0 results for 'Medco Health Solutions Inc'
Antitrust Lawyers Do Victory Lap as FTC Approves Express Scripts $29.1 Billion Deal for Medco
Shedding light on drug 'middlemen'
Just as millions of older Americans line up for new prescription drug benefits, a federal appeals court has handed states a major victory in efforts to require middlemen to disclose any special favors they receive in negotiating large drug contracts.Sidley, Milbank Lead on SXC's $4.4 Billion Catalyst Buy
In a deal that means more consolidation for the health care industry, SXC Health Solutions will buy rival pharmacy-benefits manager Catalyst Health Solutions. Fried Frank, along with Canadian firms Stikeman Elliott and Heenan Blaikie are also advising on the transaction.'Antagonistic Interests' Raise Questions About Settlement
A federal appeals court in Manhattan has ordered a trial judge to reconsider his certification of a class and his approval of a $42.5 million settlement agreement in an action brought under the Employee Retirement Income Security Act (ERISA).'Antagonistic Interests' Raise Questions About $42.5 Million ERISA Settlement
The 2nd Circuit has ordered a trial judge to reconsider his certification of a class and his approval of a $42.5 million settlement agreement in an action brought under ERISA. A unanimous panel remanded the case to Southern District of New York Judge Charles L. Brieant, ordering him to certify a subclass of plaintiffs and to make any "necessary findings and an explanation" in support of the settlement allocation. This is the second time the 2nd Circuit has reversed Brieant's determination in the case.View more book results for the query "Medco Health Solutions Inc"
In re: Rezulin Products Liability Litigation (MDL No. 1348)
Health Providers' Rezulin Claims Dismissed; Liability Not Established by Misrepresentation to IntermediaryDismissal of $4.6 Billion Merck Securities Case Affirmed
The price of Merck & Co.'s stock took a tumble in June 2001 after the Wall Street Journal reported that a Merck subsidiary had over-reported its revenues by more than $4.6 billion. Soon after investors filed a securities fraud suit alleging that Merck had hidden the truth about the accounting scandal for months.